NEMAURA MEDICAL INC. (OTCMKTS:NMRD) Files An 8-K Regulation FD Disclosure

NEMAURA MEDICAL INC. (OTCMKTS:NMRD) Files An 8-K Regulation FD Disclosure
Item 7.01.

On March 30, 2020, Nemaura Medical Inc. (the “Company”) issued a press release providing certain business updates. A copy of the press release is attached as Exhibit 99.1 hereto. On March 30, 2020, the Company released a presentation titled Wellbeing Devices: US Market, Potential and Regulations. A copy of the presentation is attached to this Current Report on Form 8-K as Exhibit 99.2.

The information included in this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth under this Item 7.01 shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.


Nemaura Medical Inc. Exhibit
EX-99.1 2 ex99x1.htm EXHIBIT 99.1 Exhibit 99.1     Nemaura to launch new digital brand proBEAT™ in the USA,…
To view the full exhibit click here

Story continues below

About NEMAURA MEDICAL INC. (OTCMKTS:NMRD)

Nemaura Medical, Inc. is a holding company. The Company owns a diagnostic medical device company specializing in discovering, developing and commercializing specialty medical devices. The Company’s focus is on the development of a continuous glucose monitoring (CGM) device, which consists of a disposable patch containing a sensor, and a non-disposable miniature electronic watch with a re-chargeable power source. CGM through a non-invasive patch can enable early detection of subtle changes in blood glucose levels. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a CGM, named sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes, and may also be used to screen pre-diabetic patients. The sugarBEAT device extracts analytes, such as glucose, to the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm.

An ad to help with our costs